Systematic evaluation of percutaneous radiofrequency ablation versus percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: a meta-analysis

详细信息    查看全文

• 作者：Rong-Hua Xu (10) (7) (9)
  Wei Gao (10) (8) (9)
  Chao Wang (10) (8) (9)
  De-Kai Guo (10) (8) (9)
  Lin Tang (10) (8) (9)
  Hui Zhang (10) (8) (9)
  Cong-Jun Wang (10) (8) (9)
  
  10. Translational Oncology Program ; University of Michigan Medical School ; 1600 Huron Parkway ; Ann Arbor ; MI ; 48109 ; Michigan ; USA
  7. Department of Oncology Surgery ; the Affiliated Hospital of Hainan Medical College ; 31 Longhua Road ; Haikou ; 570102 ; Hainan Province ; China
  9. Departments of Surgery ; University of Michigan Medical School ; 1500 E Medical Center Dr ; Ann Arbor ; 48105 ; Michigan ; USA
  8. Department of Hepatobiliary and Pancreatic Diseases ; Shanghai East Hospital ; Tongji University School of Medicine ; 150 Jimo Road ; Pudong New District ; Shanghai ; 200120 ; China
  
• 关键词：percutaneous radiofrequency ablation ; percutaneous ethanol injection ; small hepatocellular carcinoma ; system evaluation ; meta ; analysis
• 刊名：European Journal of Medical Research
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：19
• 期：1
• 全文大小：1,305 KB
• 参考文献：1. Jemal, A, Bray, F, Center, MM, Ferlay, J, Ward, E, Forman, D (2011) Global cancer statistics. CA Cancer J Clin 61: pp. 69-90 CrossRef
  2. El-Serag, HB, Mason, AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: pp. 745-750 CrossRef
  3. Bosch, FX, Ribes, J, D铆az, M, Cl茅ries, R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127: pp. S5-S16 CrossRef
  4. Sangiovanni, A, Del Ninno, E, Fasani, P, De Fazio, C, Ronchi, G, Romeo, R, Morabito, A, De Franchis, R, Colombo, M (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126: pp. 1005-1014 CrossRef
  5. Curley, SA, Izzo, F, Delrio, P, Ellis, LM, Granchi, J, Vallone, P, Fiore, F, Pignata, S, Daniele, B, Cremona, F (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230: pp. 1 CrossRef
  6. Wong, SL, Mangu, PB, Choti, MA, Crocenzi, TS, Dodd, GD, Dorfman, GS, Eng, C, Fong, Y, Giusti, AF, Lu, D (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28: pp. 493-508 CrossRef
  7. Goldberg, SN (2001) Radiofrequency tumor ablation: principles and techniques. Eur J Ultrasound 13: pp. 129-147 CrossRef
  8. Lin, S-M, Lin, C-J, Lin, C-C, Hsu, C-W, Chen, Y-C (2004) Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma鈥夆墹鈥?聽cm. Gastroenterology 127: pp. 1714-1723 CrossRef
  9. Lin, S, Lin, C, Lin, C, Hsu, C, Chen, Y (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3聽cm or less. Gut 54: pp. 1151-1156 CrossRef
  10. Shiina, S, Teratani, T, Obi, S, Sato, S, Tateishi, R, Fujishima, T, Ishikawa, T, Koike, Y, Yoshida, H, Kawabe, T (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: pp. 122-130 CrossRef
  11. Bouza, C, L贸pez-Cuadrado, T, Alc谩zar, R, Saz-Parkinson, Z, Amate, JM (2009) Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 9: pp. 31 CrossRef
  12. Shuster JJ: Review: Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0, published 3/2011. In / Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1. 0, updated March 2011. Edited by: Higgins JPT, Green S. The Cochrane Collaboration; [http://www.cochrane-handbook.org]
  13. Brunello, F, Veltri, A, Carucci, P, Pagano, E, Ciccone, G, Moretto, P, Sacchetto, P, Gandini, G, Rizzetto, M (2008) Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroentero 43: pp. 727-735 CrossRef
  14. Giorgio, A, Di Sarno, A, De Stefano, G, Scognamiglio, U, Farella, N, Mariniello, A, Esposito, V, Coppola, C, Giorgio, V (2011) Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res 31: pp. 2291-2295
  15. Lencioni, RA, Allgaier, HP, Cioni, D, Olschewski, M, Deibert, P, Crocetti, L, Frings, H, Laubenberger, J, Zuber, I, Blum, HE (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol Injection1. Radiology 228: pp. 235-240 CrossRef
  16. Lu, DS, Yu, NC, Raman, SS, Lassman, C, Tong, MJ, Britten, C, Durazo, F, Saab, S, Han, S, Finn, R (2005) Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 41: pp. 1130-1137 CrossRef
  17. Huang, G-T, Lee, P-H, Tsang, Y-M, Lai, M-Y, Yang, P-M, Hu, R-H, Chen, P-J, Kao, J-H, Sheu, J-C, Lee, C-Z (2005) Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242: pp. 36 CrossRef
  18. Cho, YK, Kim, JK, Kim, MY, Rhim, H, Han, JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49: pp. 453-459 CrossRef
  19. Grazi, G, Cescon, M, Ravaioli, M, Ercolani, G, Gardini, A, Del Gaudio, M, Vetrone, G, Cavallari, A (2003) Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long鈥抰erm survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 17: pp. 119-129 CrossRef
  20. Kurokohchi, K, Watanabe, S, Masaki, T, Hosomi, N, Miyauchi, Y, Himoto, T, Kimura, Y, Nakai, S, Deguchi, A, Yoneyama, H (2005) Comparation between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma. World J Gastroenterol 11: pp. 1426 CrossRef
  21. Shen, A, Zhang, H, Tang, C, Chen, Y, Wang, Y, Zhang, C, Wu, Z (2013) A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3聽cm. J Gastroenterol Hepatol 28: pp. 793-800 CrossRef
  22. Takahashi, S, Kudo, M, Chung, H, Inoue, T, Ishikawa, E, Kitai, S, Tatsumi, C, Ueda, T, Minami, Y, Ueshima, K (2007) Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 72: pp. 98-103 CrossRef
  23. Livraghi, T, Meloni, F, Di Stasi, M, Rolle, E, Solbiati, L, Tinelli, C, Rossi, S (2008) Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. Hepatology 47: pp. 82-89 CrossRef
  24. Ng, KK, Poon, RT, Lo, C-M, Yuen, J, Tso, WK, Fan, S-T (2008) Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 12: pp. 183-191 CrossRef
  25. Crocetti, L, Lencioni, R (2008) Thermal ablation of hepatocellular carcinoma. Cancer Imaging 8: pp. 19 CrossRef
  26. McCarthy, M, Abecasis, G, Cardon, L (2008) Recurrence of hepatocellular carcinoma. Allergy 8: pp. 169-182
  
• 刊物主题：Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：2047-783X

文摘

Background Radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) have been used for patients with hepatocellular carcinoma (HCC). However, which therapy is superior remains to be further elucidated. We aimed to conduct a systematic review to assess survival and local tumor recurrence rate with RFA compared with PEI therapy for HCC. Methods We conducted systematic review and meta-analysis of randomized controlled trials (RCTs) published up to 2014 in PubMed, MEDLINE, EMBASE, EBSCO, Springer, Ovid and the Cochrane library. Only RCTs that evaluated survival rate and occurrence of HCC between RFA and PEI therapy were included. The OR (odds ratio) with a 95% confidence interval (CI) was calculated by the Revman 5.0 software. Results A total of six studies including 983 HCC patients were eligible for this analysis. The survival rate showed a significant benefit under RFA therapy over PEI at 1-year (P = 0.02, OR = 1.88, 95% CI: 1.09 to 3.22), 2-years (P = 0.0003, OR = 2.06, 95% CI: 1.39 to 3.05) and 3-years (P = 0.0007, OR = 1.68, 95% CI: 1.25 to 2.27). Likewise, RFA achieved significantly lower rates of local tumor recurrence over PEI at 1-year (P = 0.002, OR = 0.43, 95% CI: 0.26 to 0.73), 2-year (P = 0.03, OR = 0.33, 95% CI: 0.12 to 0.88) and 3-year (P = 0.003, OR = 0.61, 95% CI: 0.43 to 0.84). Conclusions The current evidence suggests that RFA is superior to PEI in better survival and local disease control for small HCCs